- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573920
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Cohorts will consist of patients with:
- IgA nephropathy (IgAN) with urine protein:creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g
- Focal segmental glomerulosclerosis (FSGS)
- Alport syndrome
- Diabetic kidney disease (DKD) on top of background care of a RAS inhibitor and SGLT2 inhibitor
Additional cohorts may be added as data is available.
Approximately 100 patients will be enrolled in the study. Approximately 20 patients will be enrolled in each cohort to receive 0.75 mg atrasentan QD for 52 weeks. The study will also evaluate efficacy and safety of 1.5 mg atrasentan QD in FSGS subjects who received 0.75 mg atrasentan and it was well tolerated.
Patients will be allowed to continue into treatment extension and receive oral atrasentan QD for up to an additional 84 weeks (total maximum treatment of 188 weeks),
The primary objective of the study is to evaluate the effect of atrasentan on proteinuria (for IgAN, FSGS, and Alport syndrome patients) or albuminuria (for DKD patients) levels. Exploratory objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability. To facilitate study participation over this time period, where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Chinook Therapeutics
- Phone Number: (206) 485-7051
- Email: clinicaltrials@chinooktx.com
Study Locations
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
- Renal Research
-
St. Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women'S Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Health- Monash Medical Centre
-
Reservoir, Victoria, Australia, 3073
- Melbourne Renal Research Group
-
St Albans, Victoria, Australia, 3021
- Sunshine Hospital
-
-
-
-
Lazio
-
Rome, Lazio, Italy, 00165
- Ospedale Pediatrico Bambino Gesù
-
-
Lombardy
-
Pavia, Lombardy, Italy, 27100
- Fondazione Salvatore Maugeri IRCCS
-
-
-
-
-
Gangdong, Korea, Republic of
- Kyung Hee University Hospital at Gangdong
-
Gyeonggi-do, Korea, Republic of, 14068
- Hallym University Sacred Heart Hospital
-
Seoul, Korea, Republic of, 3722
- Severance Hospital, Yonsei University
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
-
Chungcheongnam-do
-
Cheonan-si, Chungcheongnam-do, Korea, Republic of, 31151
- Soonchunhyang University Hospital Cheonan
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
-
Galicia
-
Lugo, Galicia, Spain, 27004
- Hospital Ribera Polusa
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta del Hierro Majadahonda
-
-
Valencia
-
Sagunto, Valencia, Spain, 46520
- Hospital de Sagunto
-
-
-
-
-
Sheffield, United Kingdom, S5 7AU
- Sheffield Teaching Hospitals NHS
-
-
England
-
London, England, United Kingdom
- Royal Hospital London
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35805
- Apogee Clinical Research, LLC
-
-
California
-
Glendale, California, United States, 91204
- Kidney Disease Medical Group
-
Los Angeles, California, United States, 90022
- Academic Medical Research Institute
-
San Dimas, California, United States, 91773
- North America Research Institute
-
Stanford, California, United States, 94305
- Stanford University
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Colorado Kidney Care, P.C.
-
-
Florida
-
Coral Springs, Florida, United States, 33701
- South Florida Nephrology Research
-
Temple Terrace, Florida, United States, 33637
- Elixia Tampa, LLC
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Fides Clinical Research - North Atlanta Kidney Specialist
-
-
Illinois
-
Hinsdale, Illinois, United States, 60521
- NANI Research, LLC
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Northwest Louisiana Nephrology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Health Clinical Research Unit- A UMPhysicians Clinic
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Davita Clinical Research
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Mountain Kidney and Hypertension Associates
-
Winston-Salem, North Carolina, United States, 27103
- Brookview Hills Research Associates, LLC
-
-
Texas
-
Dallas, Texas, United States, 75246
- Renal Disease Research Institute, LLC
-
El Paso, Texas, United States, 79925
- El Paso Kidney Specialists
-
Houston, Texas, United States, 77054
- Prolato Clinical Research Center
-
San Antonio, Texas, United States, 78258
- San Antonio Kidney Disease Center Physicians Group, P.L.L.C
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and older for patients in the IgAN, FSGS, and Alport Syndrome cohorts
- Age 18-70 years for patients in the DKD cohort
- Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks.
For patients enrolling in IgAN Cohort:
- Biopsy-proven IgA nephropathy
- UPCR between 0.5 to less than 1.0 g/g
- Screening eGFR ≥ 30 mL/min/1.73 m2
For patients enrolling in FSGS Cohort:
- Biopsy-proven FSGS or documented genetic mutation in a podocyte protein associated with FSGS
- UPCR > 1.0 g/g
- Screening eGFR ≥ 30 mL/min/1.73 m2
- Subjects receiving systemic corticosteroids or other immunosuppressants must be on a stable dose for at least 12 weeks.
- BMI ≤ 40 kg/m2
For patients enrolling in Alport syndrome Cohort:
- Diagnosis of Alport syndrome by genetic testing
- UPCR > 0.5 g/g
- Screening eGFR ≥ 30 mL/min/1.73 m2
For patients enrolling in DKD Cohort:
- Diagnosis of type 2 diabetes mellitus
- UACR ≥ 0.5 g/g
- Screening eGFR ≥ 45 mL/min/1.73 m2
- Receiving a stable dose of SGLT2 inhibitor for at least 12 weeks
- Willing and able to provide informed consent and comply with all study requirements
Exclusion Criteria:
- Current diagnosis of another cause of chronic kidney disease or another primary glomerulopathy.
- History of kidney transplantation or other organ transplantation.
- Except for FSGS patients, use of systemic immunosuppressant medications, such as steroids, for more than 2 weeks in the past 3 months.
- Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator.
- History of heart failure or a previous hospital admission for fluid overload.
- Clinically significant history of liver disease as assessed by the Investigator.
- Hemoglobin below 9 g/dL as measured by the Investigator or blood transfusion for anemia within the past 3 months.
- Clinical diagnosis of nephrotic syndrome
- Malignancy within the past 5 years. Exception to the criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ.
- For women, pregnant, breastfeeding, or intent to become pregnant during the study.
- For men, intent to father a child or donate sperm during the study.
- Recently received an investigational agent.
- Clinically significant unstable or uncontrolled medical condition as assessed by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atrasentan 0.75 mg
Once daily oral administration of 0.75 mg atrasentan
|
Film-coated tablet
Other Names:
|
Experimental: Atrasentan 1.5 mg
Once daily oral administration 1.5 mg atrasentan (FSGS cohorts only)
|
Film-coated tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QD
Time Frame: Up to Week 12 or approximately 3 months
|
The change in urine protein:creatinine ratio (UPCR) from baseline to Week 12
|
Up to Week 12 or approximately 3 months
|
Change in albuminuria for DKD patients
Time Frame: Up to Week 12 or approximately 3 months
|
The change in urine albumin:creatinine ratio (UACR) from baseline to Week 12
|
Up to Week 12 or approximately 3 months
|
Change in proteinuria for FSGS patients at 1.5 mg dose
Time Frame: Up to Week 24 or approximately 6 months
|
The change in urine protein:creatinine ratio (UPCR) from baseline to Week 24
|
Up to Week 24 or approximately 6 months
|
Change in proteinuria for FSGS patients at 1.5 mg dose
Time Frame: Up to Week 30 or approximately 7.5 months
|
The change in urine protein:creatinine ratio (UPCR) from baseline to Week 30
|
Up to Week 30 or approximately 7.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yasmin Brahmbhatt, MD, Chinook Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Endocrine System Diseases
- Urogenital Abnormalities
- Congenital Abnormalities
- Diabetes Complications
- Diabetes Mellitus
- Connective Tissue Diseases
- Nephritis
- Glomerulonephritis
- Collagen Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Diabetic Nephropathies
- Glomerulosclerosis, Focal Segmental
- Glomerulonephritis, IGA
- Nephritis, Hereditary
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Endothelin Receptor Antagonists
- Endothelin A Receptor Antagonists
- Atrasentan
Other Study ID Numbers
- CHK01-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
Universidad Estatal de MilagroSecretaría de Ciencia, Tecnología e Innovación (Senescyt); PROMETEOUnknownKidney Diseases | Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Chronic Kidney DiseaseEcuador
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingDiabetic Nephropathies
Clinical Trials on Atrasentan
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Nephropathy | Chronic Kidney DiseaseJapan
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Nephropathy | Chronic Kidney DiseaseUnited States, Puerto Rico
-
Mayo ClinicNational Institutes of Health (NIH)CompletedEndothelial DysfunctionUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Chinook Therapeutics, Inc.RecruitingImmunoglobulin A Nephropathy | IgA NephropathySpain, Australia, United States
-
Chinook Therapeutics U.S., Inc.Active, not recruitingImmunoglobulin A Nephropathy | IgA NephropathyUnited States, Spain, Canada, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Australia, Germany, France, India, Japan, Czechia, Argentina, Italy, Colombia, Ireland, Brazil, Poland, Portugal
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedProstate Cancer | Metastatic CancerUnited States
-
AbbottCompletedProstatic NeoplasmsUnited States, Canada